{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:39:35Z","timestamp":1792273175908,"version":"4.4.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007111","name":"University of California Los Angeles Henry Samueli School of Engineering and Applied Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.drudis.2021.02.027","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T07:30:16Z","timestamp":1615102216000},"page":"1437-1449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Advanced nanodelivery platforms for topical ophthalmic drug delivery"],"prefix":"10.1016","volume":"26","author":[{"given":"Shima","family":"Gholizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7746-0409","authenticated-orcid":false,"given":"Ziqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7086-5753","authenticated-orcid":false,"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Dana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-1202","authenticated-orcid":false,"given":"Nasim","family":"Annabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.02.027_bib0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/jop.1986.2.67","article-title":"Review: topical ocular drug delivery: recent developments and future challenges","volume":"2","author":"Lee","year":"1986","journal-title":"J. Ocul. Pharmacol."},{"issue":"188","key":"10.1016\/j.drudis.2021.02.027_bib0010","article-title":"Ocular drug delivery: a clue from nanotechnology","volume":"3","author":"Bucolo","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2021.02.027_bib0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1442-9071.2000.00237.x","article-title":"Adverse effects of topical antiglaucoma drugs on the ocular surface","volume":"28","author":"Arici","year":"2000","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.drudis.2021.02.027_bib0020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archopht.1945.00890170054004","article-title":"The use of methyl cellulose in ophthalmology","volume":"33","author":"Swan","year":"1945","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.drudis.2021.02.027_bib0025","first-page":"322","article-title":"Acceptability of thickened eye drops to human subjects","volume":"33","author":"Dudinski","year":"1983","journal-title":"Curr. Ther. Res."},{"key":"10.1016\/j.drudis.2021.02.027_bib0030","first-page":"358","article-title":"Biomaterials in ophthalmic drug delivery","volume":"42","author":"Sintzel","year":"1996","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0378-5173(91)90319-J","article-title":"Concept and development of ophthalmic pseudo-lattices triggered by pH","volume":"77","author":"Ibrahim","year":"1991","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0378-5173(89)90305-0","article-title":"Gelrite: a novel, ion-activated in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol","volume":"57","author":"Rozier","year":"1989","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0378-5173(82)90114-4","article-title":"Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits","volume":"12","author":"Miller","year":"1982","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0169-409X(95)00013-W","article-title":"Bioadhesive and phase\u2013change polymers for ocular drug delivery","volume":"16","author":"Robinson","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2021.02.027_bib0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/03639049509048095","article-title":"New ophthalmic drug delivery systems","volume":"21","author":"Le Bourlais","year":"1995","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1081\/DDC-120002997","article-title":"Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery","volume":"28","author":"Kaur","year":"2002","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0065","unstructured":"Lomb, B. LOTEMAX \u00ae GEL. Retrieved from https:\/\/www.lotemaxgel.com\/hcp."},{"key":"10.1016\/j.drudis.2021.02.027_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41536-018-0061-4","article-title":"Sustained release of decorin to the surface of the eye enables scarless corneal regeneration","volume":"3","author":"Hill","year":"2018","journal-title":"NPJ Regener. Med."},{"key":"10.1016\/j.drudis.2021.02.027_bib0075","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1039\/b605640g","article-title":"Polymeric materials for ophthalmic drug delivery: trends and perspectives","volume":"16","author":"Barbu","year":"2006","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.drudis.2021.02.027_bib0080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drudis.2007.10.021","article-title":"Nanotechnology in ocular drug delivery","volume":"13","author":"Sahoo","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2021.02.027_bib0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/jop.2018.0138","article-title":"ISOPT clinical hot topic panel discussion on ocular drug delivery","volume":"35","author":"Kompella","year":"2019","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2021.02.027_bib0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2018.06.031","article-title":"Polymer-based carriers for ophthalmic drug delivery","volume":"285","author":"Julieta","year":"2018","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.drudis.2021.02.027_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2020.01.057","article-title":"Advances and limitations of drug delivery systems formulated as eye drops","volume":"321","author":"Jumelle","year":"2020","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.drudis.2021.02.027_bib0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2017.12.017","article-title":"Ophthalmic gels: past, present and future","volume":"126","author":"Al-Kinani","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2021.02.027_bib0105","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1167\/iovs.02-0791","article-title":"Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression","volume":"44","author":"Kompella","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2021.02.027_bib0110","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/adt.2018.911","article-title":"Micro\/nanoparticle delivery systems for ocular diseases","volume":"17","author":"Halasz","year":"2019","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.drudis.2021.02.027_bib0115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0169-409X(95)00013-W","article-title":"Bioadhesive and phase-change polymers for ocular drug delivery","volume":"16","author":"Robinson","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2021.02.027_bib0120","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.addr.2005.07.005","article-title":"The use of mucoadhesive polymers in ocular drug delivery","volume":"57","author":"Ludwig","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2021.02.027_bib0125","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1021\/js9504189","article-title":"Effect of benzalkonium chloride\/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits","volume":"85","author":"Madhu","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2021.02.027_bib0130","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000065608","article-title":"Enhanced ocular anti-in\ufb02ammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspension","volume":"34","author":"Bucolo","year":"2002","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.drudis.2021.02.027_bib0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0928-0987(02)00057-X","article-title":"Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen","volume":"16","author":"Pignatello","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2021.02.027_bib0140","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1016\/S0142-9612(02)00080-7","article-title":"Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application","volume":"23","author":"Pignatello","year":"2002","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2021.02.027_bib0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejpb.2005.07.002","article-title":"Ophthalmic delivery systems based on drug-polymer-polymer ionic ternary interaction: in vitro and in vivo characterization","volume":"62","author":"Sandri","year":"2006","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/1874104500802010066","article-title":"Transcorneal permeation in a corneal device of nonsteroidal anti-in\ufb02ammatory drugs in drug delivery systems","volume":"2","author":"Valls","year":"2008","journal-title":"Open Med. Chem. J."},{"key":"10.1016\/j.drudis.2021.02.027_bib0155","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/jps.20685","article-title":"Flurbiprofen loaded biodegradable nanoparticles for ophthalmic administration","volume":"95","author":"Vega","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2021.02.027_bib0160","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-5173(01)00760-8","article-title":"Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A","volume":"224","author":"De Campos","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0165","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/jop.2012.0200","article-title":"Novel strategies for anterior segment ocular drug delivery","volume":"29","author":"Kishore","year":"2013","journal-title":"J. Ocular Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2021.02.027_bib0170","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/polym10040425","article-title":"Novel nano-liposome formulation for dry eyes with components similar to the preocular tear film","volume":"10","author":"Torre","year":"2018","journal-title":"Polymers"},{"key":"10.1016\/j.drudis.2021.02.027_bib0175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijpharm.2005.05.036","article-title":"Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate","volume":"301","author":"Yamaguchi","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0180","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijpharm.2007.07.045","article-title":"Preparation of rapamycin-loaded chitosan\/PLA nanoparticles for immunosuppression in corneal transplantation","volume":"349","author":"Yuan","year":"2008","journal-title":"Int. J. Pharm"},{"key":"10.1016\/j.drudis.2021.02.027_bib0185","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijpharm.2007.03.011","article-title":"Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs","volume":"340","author":"Kassem","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0190","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1002\/jps.22137","article-title":"A nonionic surfactant\/chitosan micelle system in an innovative eye drop formulation","volume":"99","author":"Pepic","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2021.02.027_bib0195","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/js950474+","article-title":"Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers","volume":"85","author":"Calvo","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2021.02.027_bib0200","unstructured":"Eldien, H.M. A randomized controlled trial comparing urea loaded nanoparticles to placebo: a new concept for cataract management. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03001466. [Accessed 18 February 2021]."},{"key":"10.1016\/j.drudis.2021.02.027_bib0205","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1167\/iovs.14-14700","article-title":"Design and characterization of an ocular topical liposomal preparation to replenish the lipids of the tear film","volume":"55","author":"la-Torre","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2021.02.027_bib0210","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1023\/A:1018936205485","article-title":"Poly(\u03b5-caprolactone) nanocapsules in carteolol ophthalmic delivery","volume":"10","author":"Heussler","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2021.02.027_bib0215","unstructured":"Popov, A. et al. Compositions and methods for ophthalmic and\/or other applications. Retrieved from https:\/\/patents.justia.com\/patent\/9827191. [Accessed 18 February 2021]."},{"key":"10.1016\/j.drudis.2021.02.027_bib0220","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0091270006292626","article-title":"Comparison of the stability, efficacy, and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation","volume":"1","author":"Gonzalez","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2021.02.027_bib0225","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejmech.2009.10.017","article-title":"Designing dendrimers for ocular drug delivery","volume":"1","author":"Spataro","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drudis.2021.02.027_bib0230","series-title":"Ocular Drug Delivery","author":"Vadlapudi","year":"2015"},{"key":"10.1016\/j.drudis.2021.02.027_bib0235","unstructured":"Mitra A.K. et al. Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors. US Patent 8 435 544."},{"key":"10.1016\/j.drudis.2021.02.027_bib0240","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/jop.2013.0157","article-title":"Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility","volume":"30","author":"Vadlapudi","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2021.02.027_bib0245","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijpharm.2017.01.020","article-title":"Synthesis, characterization, and in-vitro antitumor activity of the polyethylene glycol (350 and 1000) succinate derivatives of the tocopherol and tocotrienol isomers of Vitamin E","volume":"519","author":"Abu-Fayyad","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0250","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1517\/17425247.2013.796360","article-title":"Applications of poloxamers in ophthalmic pharmaceutical formulations: an overview","volume":"10","author":"Almeida","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.drudis.2021.02.027_bib0255","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijpharm.2006.12.038","article-title":"Development of a poloxamer analogs\/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin","volume":"337","author":"Qi","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0260","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijpharm.2003.11.032","article-title":"Micellar solutions of triblock copolymer surfactants with pilocarpine","volume":"272","author":"Pepic","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0265","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijpharm.2011.01.004","article-title":"Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly (ethylene glycol)-hexyl-substituted poly (lactide) micelle carriers","volume":"416","author":"Di Tommaso","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0270","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejps.2010.02.006","article-title":"Investigations on the lyophilisation of MPEG-hexPLA micelle based pharmaceutical formulations","volume":"40","author":"Tommaso","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2021.02.027_bib0275","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acs.molpharmaceut.6b00445","article-title":"Prolonged ocular retention of mucoadhesive nanoparticle eye drop formulation enables treatment of eye diseases using significantly reduced dosage","volume":"13","author":"Liu","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2021.02.027_bib0280","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1073\/pnas.0608611104","article-title":"Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus","volume":"104","author":"Lai","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2021.02.027_bib0285","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2021.02.027_bib0290","unstructured":"Popov, A. et al. Kala Pharmaceuticals, Inc. Johns Hopkins University. Pharmaceutical nanoparticles showing improved mucosal transport. World Patent Application WO\/2013\/166385."},{"key":"10.1016\/j.drudis.2021.02.027_bib0295","series-title":"Kala pharmaceuticals announces completion of enrollment of STRIDE 3 trial for EYSUVIS\u2122 (KPI-121 0.25%) for dry eye disease","author":"Kala Pharmaceuticals","year":"2020"},{"key":"10.1016\/j.drudis.2021.02.027_bib0300","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40123-014-0021-z","article-title":"Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation","volume":"3","author":"Schopf","year":"2014","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.drudis.2021.02.027_bib0305","first-page":"299","article-title":"Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop","volume":"7","author":"Coffey","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.drudis.2021.02.027_bib0310","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41551-020-00606-8","article-title":"Gelling hypotonic polymer solution for extended topical drug delivery to the eye","volume":"4","author":"Kim","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.drudis.2021.02.027_bib0315","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1021\/acs.biomac.6b00054","article-title":"Phenylboronic-Acid-based polymeric micelles for mucoadhesive anterior segment ocular drug delivery","volume":"17","author":"Prosperi-Porta","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.drudis.2021.02.027_bib0320","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1167\/iovs.07-1077","article-title":"Novel hyaluronic acid\u2013chitosan nanoparticles for ocular gene therapy","volume":"49","author":"De la Fuente","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2021.02.027_bib0325","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1167\/iovs.05-0495","article-title":"Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance","volume":"47","author":"Enriquez de Salamanca","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2021.02.027_bib0330","first-page":"1185","article-title":"Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model","volume":"12","author":"Kompella","year":"2006","journal-title":"Mol. Vis."},{"key":"10.1016\/j.drudis.2021.02.027_bib0335","first-page":"455","article-title":"Pilocarpine dispensation for the soft hydrophilic contact lens","volume":"59","author":"Ruben","year":"1975","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.drudis.2021.02.027_bib0340","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/00006324-199312000-00004","article-title":"Continuous drug delivery through the use of disposable contact lenses","volume":"70","author":"Lesher","year":"1993","journal-title":"Optom. Vis. Sci."},{"key":"10.1016\/j.drudis.2021.02.027_bib0345","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/archopht.1974.01010010425011","article-title":"Ocular penetration of prednisolone and the hydrophilic contact lens","volume":"92","author":"Hull","year":"1974","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.drudis.2021.02.027_bib0350","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/ma11071125","article-title":"Therapeutic contact lenses with polymeric vehicles for ocular drug delivery: a review","volume":"11","author":"Choi","year":"2018","journal-title":"Materials"},{"key":"10.1016\/j.drudis.2021.02.027_bib0355","unstructured":"Gaylord, N.G. Polycon Labor Inc US, Polycon Laboratories. Oxygen-permeable contact lens composition, methods and article of manufacture. US Patent 3808178."},{"key":"10.1016\/j.drudis.2021.02.027_bib0360","unstructured":"Philip, L.K. et al. Bausch and Lomb Inc. Hydrophilic contact lens made from polysiloxanes which are thermally bonded to polymerizable groups and which contain hydrophilic sidechains. US Patent 4260725."},{"key":"10.1016\/j.drudis.2021.02.027_bib0365","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1002\/pola.23607","article-title":"Hydrogels from soft contact lenses and implants to self-assembled nanomaterial","volume":"47","author":"Kopecek","year":"2009","journal-title":"J. Polym. Sci. A Polym. Chem."},{"key":"10.1016\/j.drudis.2021.02.027_bib0370","doi-asserted-by":"crossref","first-page":"34194","DOI":"10.1038\/srep34194","article-title":"Ocular drug delivery through pHEMA-hydrogel contact lenses co-loaded with lipophilic vitamins","volume":"6","author":"Lee","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2021.02.027_bib0375","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1016\/j.biomaterials.2010.01.113","article-title":"Extended delivery of hydrophilic drugs from silicone\u2013hydrogel contact lenses containing vitamin E diffusion barriers","volume":"31","author":"Peng","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2021.02.027_bib0380","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.biomaterials.2008.10.032","article-title":"Surfactant-laden soft contact lenses for extended delivery of ophthalmic drugs","volume":"30","author":"Kapoor","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2021.02.027_bib0385","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41578-019-0148-6","article-title":"Hydrogel microparticles for biomedical applications","volume":"5","author":"Daly","year":"2020","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.drudis.2021.02.027_bib0390","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1167\/iovs.07-0066","article-title":"Coated microneedles for drug delivery to the eye","volume":"48","author":"Jiang","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"13","key":"10.1016\/j.drudis.2021.02.027_bib0395","first-page":"3191","article-title":"Ocular drug delivery using microneedles","volume":"48","author":"Prausnitz","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2021.02.027_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-06981-w","article-title":"Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery","volume":"9","author":"Than","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drudis.2021.02.027_bib0405","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.bios.2016.12.062","article-title":"Microfluidic approaches for isolation, detection, and characterization of extracellular vesicles: current status and future directions","volume":"91","author":"Gholizadeh","year":"2017","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.drudis.2021.02.027_bib0410","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13287-019-1372-0","article-title":"Recent advances of exosomes in immune-mediated eye diseases","volume":"10","author":"Li","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.drudis.2021.02.027_bib0415","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.actbio.2018.01.011","article-title":"Short peptide analogs as alternatives to collagen in pro-regenerative corneal implants","volume":"69","author":"Jangamreddy","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.drudis.2021.02.027_bib0420","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharmthera.2017.02.020","article-title":"Exosomes: therapy delivery tools and biomarkers of diseases","volume":"174","author":"Barile","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2021.02.027_bib0425","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.biomaterials.2016.09.031","article-title":"Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA","volume":"111","author":"Morishita","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2021.02.027_bib0430","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.4155\/tde.14.75","article-title":"Advances in ophthalmic drug delivery","volume":"5","author":"Morrison","year":"2014","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.drudis.2021.02.027_bib0435","article-title":"Dual hydrophobe and phenylboronic acid-grafted poly (vinylpyrrolidone) polymers as shear-thinning and mucoadhesive eyedrop formulations","author":"Mokhtari","year":"2016","journal-title":"Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress"},{"key":"10.1016\/j.drudis.2021.02.027_bib0440","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/scipharm87030015","article-title":"Current approaches to use cyclodextrins and mucoadhesive polymers in ocular drug delivery\u2014a mini-review","volume":"87","author":"B\u00edr\u00f3","year":"2019","journal-title":"Sci. Pharm."},{"issue":"1-2","key":"10.1016\/j.drudis.2021.02.027_bib0445","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0168-3659(99)00233-3","article-title":"Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces","volume":"65","author":"Huang","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2021.02.027_bib0450","unstructured":"Bergmann Koury, C. RX Perspective: nanoparticle \u2018amplifies\u2019 drug efficacy. www.ophthalmologymanagement.com\/issues\/2019\/may-2019\/rx-perspective. [Accessed 18 February 2021]."},{"key":"10.1016\/j.drudis.2021.02.027_bib0455","unstructured":"Racaniello, V. (2009) Influenza virus attachment to cells. www.virology.ws\/2009\/05\/04\/influenza-virus-attachment-to-cells\/. [Accessed 18 February 2021]."},{"key":"10.1016\/j.drudis.2021.02.027_bib0460","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13065-014-0060-5","article-title":"Boronic acids for sensing and other applications-a mini-review of papers published in 2013","volume":"8","author":"Lacina","year":"2014","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.drudis.2021.02.027_bib0465","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/ar300130w","article-title":"Exploiting the reversible covalent bonding of boronic acids: recognition, sensing, and assembly","volume":"46","author":"Bull","year":"2013","journal-title":"Acc. Chem. Res."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621001124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621001124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:49:40Z","timestamp":1761223780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621001124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1359644621001124"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.02.027","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced nanodelivery platforms for topical ophthalmic drug delivery","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}